Note: Descriptions are shown in the official language in which they were submitted.
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
FILM-FORMING RESINS AS A CARRIER FOR TOPICAL APPLICATION OF
PHARMACOLOGICALLY ACTIVE AGENTS
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
[0001] The invention relates to resin or other film-forming agent based
biological
dressings that adhere to the skin and contain one or more pharmacologically
active agents for
the treatment of symptoms relating to dermatological diseases and those
affecting mucous
membranes. The invention is exemplified by biological dressings comprising
tincture of
benzoin and clotrimazole for the treatment of athlete's foot and by biological
dressings
comprising mastic and ciclopirox for onychomycosis.
BACKGROUND INFORMATION
[0002] For many forms of dennatological conditions, the powders, sprays,
solutions,
lotions and creams available over-the-counter lack effectiveness. The reason
for this varies,
from poor delivery of the medication to the source or cause of the condition,
to loss of the
medication through abrasion from normal activity of the patient, to absorption
of medications
applied to the skin by the patient's socks or clothes. For these various
reasons, currently
available commercial medications are prone to come off easily once applied to
the affected
area, and consequently much of the medication is wasted, either through over
application in an
attempt to anticipate the problem, or in medicine quickly being dispersed away
from the site.
The medications for these conditions typically require at least 2 to 4 weeks
of continuous
treatment, and thus often fail due to this poor delivery.
[0003] A further problem with the use of existent medications is the lack of
coinpliance by
patients. Due to the mess and difficulty of use, patients will often use these
over the counter
medications only until their symptoms abate and then they will stop the
medication, before
the recommended course of treatment is completed, and hence often before the
infection has
truly cleared. Though momentarily abated, the infection then begins to take
hold again, and in
a matter of days or weeks a full blown infection occurs again. In many cases
the patient will
repeat using the over the counter medication until the symptoms clear, and
again stop the
medication with the first sign of abatement, with the wliole cycle repeating.
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
2
[0004] Hence, there is a need for a clean and inexpensive vehicle/carrier of
topically
applied medications that increases the convenience and effectiveness of the
treatment and
decreases the necessary time for the treatment. It is preferably associated
with less waste
and lower cost, and ultimately leads to improved treatment of patient symptoms
and increased
patient satisfaction.
[0005] In medicine, tincture of benzoin and mastic guni (Mastisol) have been
employed to
form a sticky coating on slcin prior to the placement of adhesive
preparations. Tincture of
benzoin has also been used to form a biologic dressing over superficial
cutaneous wounds as
well as aphtlious ulcers (canker sores). However, the general use of resins,
such as mastic and
benzoin gum, as semi-permanently applied carriers for increasing the efficacy
and usef-ulness
of topological of phannacological agents has not been disclosed.
[0006] A tincture of benzoin has been used with podophyllin resin (10-25%) in
the
treatment of genital warts. It is considered by many to be cumbersome and
inconvenient (see
USPN 5,063,065 and 5,167,649). Unfortunately, podophyllin resin is toxic, and
even when
applied in a tincture of benzoin, this agent must be removed by rigorous
washing 1 to 6 hours
post-application. Due to the problems associated with using podophyllin resin
in tincture of
benzoin, other carriers have been sought. As an exainple, in the treatment of
genital warts,
Goh, et al. (Siyzgapore Med J (1998) 39:17-19) reports that podophyllin
prepared in 0.25%
ethanol can be self-applied and is as efficacious as podophyllin prepared in
tincture of
benzoin and applied in the clinic. Use of tincture of benzoin as a biological
bandage with
compounds that it is desirable to have in long contact with the skin has not
been reported.
SUMMARY OF THE INVENTION
[0007] Compositions and methods are provided for increasing the effectiveness
of
treatment of dermatological disorders on the skin or a mucous menibrane of a
mammal by
using a resin or other film-forming agent as a carrier for a pharmacologically
active agent.
The pharmacological compositions are comprised of one or more resins or other
film-fonning
agents, at least one topically acceptable pharmacologically active agent for
treatnlent of a
dermatological disorder other than the resins or other film-forming agents,
wherein the active
agent is non-toxic to the mammal being treated when left in contact with the
lesion of interest
for greater than four hours, and a topically acceptable volatile solvent. The
compositions
optionally can include a penetration enhancer. The methods of treating
symptoms of a
dermatological disorder include the steps of contacting affected sites on the
skin or nails of a
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
3
patient in need thereof witll the pharmacological composition comprised of one
or more resins
or other film-forming agents, a pharmacological agent or agents, and an
evaporative solvent,
and allowing it to dry to form a resin-based biological dressing. The
biological dressing
comprises a sticky film of the one or more resins or other agents wliich form
a film on the skin
and a pharmacologically active agent; the latter remains on the skin, nail or
mucous membrane
after the volatile solvent has evaporated from the one or more resins or other
film-forming
composition. The dressing forms a hydrophobic, protective film that provides
sustained
release of the pharmacologically active agent at the site of application. The
invention finds use
in the treatment of dermatological disorders such as infection, inflammation,
and
hyperproliferation of epidermal cells.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 is a graphical representation showing data from a skin
penetration study
of a composition of the invention.
[0009] Figure 2 is a graphical representation showing in vitro franz cell
penetration
results.
DETAILED DESCRIPTION OF THE INVENTION
[0010] Compositions and niethods are provided for the convenient and effective
treatrnent
of at least one symptom of a dermatological disorders in a mammal,
particularly a human, in
need thereof, with a biological dressing. By "biological dressing" or
"biologic dressing" or
"biologic bandage" is intended a non-occlusive but adherent pharmacological
composition
that is formed by drying on the skin a pharmacologic composition comprised of
one or more
resins, such as benzoin, mastic or other compositions that can form a barrier
film on the skin,
such as compositions that are used as skin wound sealing agents, one or more -
pharmacologically active agents and a topically acceptable volatile solvent,
such as ethanol.
The resin-based biologic dressing forms a protective coating at the site(s) on
the skin, nails or
mucosal membrane exhibiting symptoms of the disorder and also acts as a
reservoir for the
pharmacolocally active agent(s) to provide sustained delivery of an
appropriate medication or
combination of medications to the site.
[0011] The skin disorder syinptoms to be treated include, but are not limited
to, slcin, nail
and mucosal membrane lesions, inflainmation, itching, scaling and pain. The
disorders
include viral, fungal and bacterial infections, inflaniinatory conditions, and
hyperproliferative
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
4
disorders. The pharmacological agent(s) can include topically active agents
that can be used
to ameliorate skin disorder symptoms, including antimicrobial and antiviral
agents, anti-
inflammatory agents, analgesics and anesthetics. As desired, the effectiveness
of the
pharmacological agent(s) optionally can be increased by including a skin or
nail penetration
enhancer in the pharmacologic composition.
[0012] The biological bandage is easily removed using a solvent such as
ethanol. Since
the coating that contains the medication stays in place until such deliberate
removal, the
effectiveness of the treatment is increased since the slcin is exposed to the
active ingredient for
a longer period of time. This also allows for a decreased treatment time, and,
ultimately,
improved treatment of symptoms and increased patient satisfaction. Thus,
compositions of the
invention can be used to improve delivery of medications that are soluble in
organic solvents
such as alcohols that are typically applied topically for the treatment
dermatologic disorders.
The advantages of the subject invention include a more specifically directed
application of
medications to sites affected by a skin disorder, and extended retention on
the skin of the
medication because the film is resistant to water and abrasion by clothing.
Additionally, the
vehicle is relatively inexpensive, is pleasant smelling, and the bandage can
be conveniently
and easily removed, for example with alcohol, when desired. Many
derinatological conditions
are exacerbated by moisture so the water repellent qualities of the dressing
also protect the
slcin from further damage. The resin-based biological dressings of the
invention are designed
to be directly applied to a lesion needing treatment, and left in place for an
extended period of
time, without requiring conventional adhesive bandages. It is intended that
the dressing need
only be washed from the lesion for purposes of convenience and cleanliness.
The biological
dressings of the subject invention are cleaner and easier to apply than
conventional dressings
and existing medications, have less waste and are more economical, allowing
for more
efficient, efficacious and palatable relief of symptoms or recovery from the
skin disorder
being treated. Overall treatment success is increased by decreasing the time
required for
therapy, for example for athlete's foot, from about four weeks to seven to ten
days while
decreasing the total amount of medication needed and iinproving patient
conipliance.
[0013] Further advantages of the subject invention include that various of the
resins that
find use, including benzoin and mastisol, and wound sealing agents are already
approved for
human use and have been tested and found to be safe for topical application on
non-human
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
mammals; the wound sealing agents have the advantage of being able to deliver
alcohol-
insoluble medications wliile reducing pain during application to an open
wound.
[0014] The resin-based biological dressings are prepared by drying on the
skin, a
pharmacological coinposition comprising an agent that can be used to
ameliorate the
symptoms of a dermatological disease and one or more resins dissolved in a
volatile solvent.
Generally, the pharmacological composition is prepared as a sticlcy slurry or
solution of the
combined one or more resins or film-forming agents and the phannacologically
active agent
that can be applied to a site on the skin or a mucosal membrane. The
consistency of the
pharmacological composition can be varied by adjusting the ratio of solvent to
the combined
one or more resins in the composition to achieve the desired consistency for
application to a
particular site. For areas where evaporation of solvent may be slower, for
example, application
to lesions on a mucosal membrane such as the gums, it may be desirable to
prepare the
composition as a paste and to use a more volatile solvent, whereas for
application to hard to
reach areas, such as between the toes, it maybe desirable to prepare a less
viscous
composition that can be applied thinly to the affected areas. However, for
treatment of more
severe lesions in non-visible areas, due to an athlete's foot infection for
example, application
of a more viscous preparation may be preferred. It should be understood that
some wound
sealing agents develop into a diy adhesive layer or film once in contact with
tissue, and
therefore do not generally require use of a solvent other than what may be
necessary to
properly blend in the pharmacologically active agent.
[0015] The relative proportions of the one or more resins or other film-
forming agents, the
pharmacologically active agent or agents and the evaporative solvent in the
preferred
composition can vary widely, and depend upon the specific intended use of the
biological
dressing. Precise preferred ratios depend to some extent on the rate of
release of the
pharmacologically active agent from the film, the desired stickiness of the
residual film, and
the area of application. For example, if the intended application is to an
affected area on the
face, the preferred composition would have a lower proportion of combined
resins or other
fihn-forming agents, to allow for a more thinly applied, less visible and less
sticlcy medical
dressing. Generally, the pharmacological compositions of the subject invention
will typically
have about 5% to 90% resin or other film-fonning agent, more lilcely about 20%
to 85%, 30%
to 70% or 40% to 60% resin or other fihn-forming agent. In one embodiment, the
pharmacological compositions will have about 1% to 15% resin or other film-
forming agent.
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
6
[0016] The resin-based biological dressings of the invention may also be
comprised of a
combination of multiple resins or other film-forming agents, provided that
when a non-resin
film-forrning agent is used in coinbination with a resin, the resin is the
primary matrix of the
composition. In one embodiment, the compositions of the subject invention will
comprise a
combination of one or more resins, each resin being less than 20% of the total
composition.
In some embodiments, the total concentration of the combined resins in the
compositions of
the invention will exceed 20%, and may be as mucli as 20% to 90% of the total
composition.
In other embodiments, the total concentration of the combined resins may not
exceed 20%,
and may be as little as 1% to 20% of the total composition. Accordingly, the
concentrations
of each of the resins or other film forming agents may vary so long as
toxicity to the subject
is avoided.
[0017] The stickiness of the biological dressings is provided by the use of a
combination of
one or more resins or other film-fonning agents. The resins that are usefixl
in the methods and
compositions of the invention include, but are not limited to, naturally
occurring resins and
gums, such as those that are harvested fiom trees, although gum resins also
may be prepared
by synthetic means (see for example, USPNs 5,644,049, 5,429,590 and
4,307,717).
Exemplary resins include benzoin resinous exudate harvested from Styracaceae
trees,
including Benzoin Siam from Styrax Tonkinesis and Benzoin Sumatra from Styrax
Benzoin.
Tincture of benzoin and benzoin compound tincture is readily available through
numerous
commercial sources, including many drug stores and suppliers of surgical
goods. Another
resinous tree exudate that is preferred and is commonly used in the medical
arts for enhancing
the adherence of surgical bandages, is mastic, a hard resin that is harvested
from Pistacia
lentiscus. A tincture of mastic gum (Mastisol) is produced by Ferndale
Laboratories in
Ferndale, MI and is also available through suppliers of surgical goods. Other
resins that can be
used include the gum resin exudates from Burserceae trees, including Boswellia
serrata (also
lcnown as Boswellin), Boswellia dalzielli, Boswellia carteri (olibanum gum)
and the oleoresin
Canariun2 luzonicuna or Canariuna cosnmune (Elemi gum or resin). Oleoresins
useful in the
compositions of the invention include balsain resins. Additional resinous
exudates
contemplated from other tree species include Eucalyptus species (Eucalyptus
globulus) and
Myt-taceae "Tea-tree" species (Melaleuca altern.ifolia, Leptosperrnuin
scopariuin, and Kunzea
ericoides). Many naturally occurring resins themselves have pharmacological
properties, and
their topical application may cause irritation in certain patients or
exacerbate certain
conditions. Prudent clioice of the resins to be used in preparing a particular
biological dressing
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
7
takes into consideration the disorder to be treated and the sensitivities of a
particular patient's
skin.
[0018] In addition to the resins discussed herein, biologic dressings can be
made from
several classes of adhesive polymers including acrylic polymers (e.g.
cyanoacrylates),
polyisobutylenes and silicones. Examples of the acrylic polymers include
acrylate-
vinylacrylate, dimethylaminoethylmethacrylate, methacrylic esters, N-2-
butylcyanoacrylate,
2-octylcyanoacrylate, polyacrylic acid, polyaminomethylmethacrylate and
polymethylmethacrylate. Polyisobutylenes (a sub-type of polyolefins) are
pressure sensitive
adhesives made by blending multiple molecular weights to achieve desired
adhesive and
drug-carrier properties. Silicones are available in the form of gels, liquids,
or elastomers,
depending on the nature of side groups and the interchain cross-linking. Other
potential
adhesive vehicles include hydrogel polymers such as poly (oxypropylene-co-
oxyethene)
glycol, cellulose bioadhesives such as hydroxypropylmethyl-cellulose,
synthetic laticies such
as polyvinyl acetate and ethylene vinyl-acetate, mucosal adhesives such as
polyoxyethylene,
pyroxylin solutions, and the iodophors. Commercial sources of film-forming
agents that can
be combined directly with a pharmacologically active agent include Dermabond
(Ethicon)
which is a formulation of 2-octylcyanoacrylate; Liquid Band Aid (Johnson and
Johnson) which
is also a formulation of 2-octylcyanoacrylate; Liquiderm, Soothe-N-Seal, Nexa
Band (all from
Closure Medical Co), all formulations of cyanoacrylate; "New-Slcin" (New Skin)
containing
pyroxylin; and hydrogels containing poly (oxypropylene-co-oxyethene) glycol
(MedLogic).
[0019] ' A desirable feature of the subject compositions is that they form an
adherent and
protective film or biological bandage over a dermatologic lesion. To effect
this attribute, the
pharmacological composition is prepared with a volatile solvent that
evaporates to leave a
hydrophobic coating comprised of the one or more resins or other film-forming
agents and the
phannacological agent on the skin or nail. Volatile solvents for use in the
subject
compositions include ethyl acetate, n-propyl acetate, alcohols sucli as
methanol, ethanol,
propanol, and isopropanol, ketones, such as acetone, and ethers such as
dimethyl ether. Other
evaporative compounds may also find use, so long as they are compatible with
other
coniponents of the pharmacological composition and topically acceptable to the
majority of
patients. The resins of choice are diluted in the volatile solvent such that
the concentration of
solvent comprises about 40% to 98% (v/v or v/w), more cominonly at least about
50% to
95%, 65% to 90%, 70% to 85%, preferably about 90% to 95% of the total
composition. An
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
8
exemplary composition contains a tincture of benzoin, which is comprised of
benzoin in
about 75% to 83% ethanol.
[0020] The pharmacological agent or agents included in the pharmacological
compositions
will depend upon the dermatological disorder being treated. To allow for
extended contact of
the biological dressing with the lesion under treatment, pharmacological
agents chosen should
be efficacious without being locally or systemically toxic or caustic to the
maminal to which
the medicated dressing is administered. A biological dressing of the subject
invention is
intended to remain at the site of application for greater than four hours,
more often as long as
8, 10 or 12 hours, sometimes as long as 16, 18 or 20 hours, and for certain
treatments, as long
as 24, 36 or 72 hours or even longer prior to removal. The time of treatment
desired is based
at least in part upon the nature of the condition to be treated and the
pharmacological agent(s)
that are being used. In general, the pharmacological compositions are
formulated so that the
concentration of the pharmacological agent(s) that is in the biological
bandage approximates
the concentration of agent that is used in existing topical formulations.
However, because the
adherent properties of a film-forming resin-based biological dressing allow
for extended and
continuous exposure of a skin lesion to drug, redticed concentration
formulations are possible
and in some cases preferred. The amount to be used can therefore be adjusted
as appropriate.
Generally, the amount used will be within the range of 25% of the indicated
concentration,
preferably within 10% of the indicated concentrations. In the following
paragraphs, the
percentages appearing in parenthesis after the name of a particular agent
represent the
concentration(s) of agent that is (are) used in existing topical formulations.
[0021] The subject biological dressings find particular use in treating
numerous
dermatological disorders, including superficial infections (fungal, bacterial,
viral and
parasitic), and inflammatory skin disorders. As used herein, the term "slcin"
refers to the
niembranous tissue forming the external covering or integunlent of an animal
and consisting
in vertebrates of the epidermis and dermis. As used herein, the term "nail"
refers to a
stibstructure, composed mainly of the protein keratin, of the outer layer of
the skin. As such,
"nail" includes botli "fingernails" and "toenails" of an animal. The "nail
bed" is the skin on
the top of which the nail grows. Additional uses include sustained delivery of
pharmacological agents for hair growth stimulation and hair growth
retardation, skin
pignlenting and pignientation reinoval agents, sunscreens, insect repellents,
anti-anginal, anti-
perspirant and anti-nausea agents.
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
9
[0022] Superficial fungal infections treatable by the subject compositions
include those
caused by mold-like fungi (dermatophytes or tinea) or yeast-like fungi
(Candida) that are
confined to the stratum corneum or squamous mucosa. Particularly considered is
the
treatment of tinea infections including onychomycosis (tinea unguiuin),
athlete's foot (tinea
pedis), ringworm (tinea capitis), jock itch (tinea cniris), tinea corporis,
tinea manuum and
tinea versicolor. Other dermatological fungal infections treatable with the
described
biological dressings include Candida, Epidermophyton, Mierospoz una,
Trichophyton and
Pityrospof urn infections.
[0023] Compositions for the treatment of superficial fungal infections will
include at least
one anti-fungal pharmaceutical agent. Anti-fungal agents for use in a
biological dressing
composition include those well-known in the art, such as clotrimazole (0.5% to
2.0%),
ketoconazole (0.5% to 2%), econazole (1%), miconazole (2%), terconazole
(0.4%),
butoconazole (2%), oxiconazole (1%), sulconazole (1%), ciclopirox olamine (1%
to 8%),
haloprogin (1%), tolnaftate, (1%), amphotericin B (3%), butenafine (1.0%),
terbinafine (0.5%
to 2.0%), naftifine (0.5% to 10%), nystatin and griseofulvin. References that
can be consulted
to aid in the selection of an appropriate pharmacological agent include
Goodman and
Gilman's "The Pharmacological Basis of Therapeutics", 9tt' Edition, 1996,
Pergamon Press,
New York, and the lastest edition of the Physician's Desk Reference published
by Medical
Economics Company, Montvale, NJ).
[0024] Bacterial infections that may arise can be treated simultaneously or
prophylactically by additionally including a topically compatible antibiotic
pharmacological
agent in the biological dressing. Antibiotic medications known in the art that
will find use in
preparation of the subject compositions include clindamycin (1%), erythromycin
(1.0% to
2.0%), tetracycline (1% to 3%), mupirocin (2.0%), gentamicin (0.1%),
metronidizole (0.75%,
1%), bacitracin (250 to 600 units/cc), neomycin (3.5 mg/cc) and polymyxin B
(8,000 to
12,000 units/cc). A composition with a combination of antibiotics against
different strains of
bacteria will be preferred for certain treatments. A steroidal pharmacological
agent, sucll as
betamethasone (0.025% to 0.1%), in a biological dressing intended to treat a
fungal infection
can additionally be included to enhance the retraction of the lesion.
Biological dressings
having an antibiotic medication as the primary pharmacological agent can be
prepared to treat
other slcin disorders for which such niedications are traditionally used,
including as inipetigo
contagiosa, acne vulgaris, other superficial slcin infections of unknown
etiology, and post-
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
operative superficial skin infections (e.g., infections that occur around the
insertion of a
catheter). Wound healing can be aided and colonization of wounds (i.e.
isolated areas with
first-degree bums) can be inhibited by application of a biological dressing
comprising silver
sulfadiazine (1%). The particular antibiotic selected to be included in the
biologic dressing
will of course depend on the agents to which the strain of bacteria causing
the infection is
sensitive, and the specific needs of the patient.
[0025] A biologic dressing can also be prepared for the treatment of
superficial parasitic
infections, such as scabies, nits and lice (including head lice and crab
lice). For treating such
infections, pharmacological compositions comprising miticides or pediculocides
such as
crotamiton (10%) or permethrin (5%), lindane (1%), malathion (0.003% to 0.5%),
benzyl
benzoate (26% to 30%), thiabendazole and pyrethrins.
[0026] For treating pain associated with arthritis, joint inflammation and
muscle pain a
composition of the invention can be prepared comprising one or more resins or
other film-
forming agents and one or more active ingredients such as menthol (10%),
methyl salicylate
(10%) and capsaicin (0.01%-10%) or a corticosteriod (see below for appropriate
compounds
and dosages). The compositions of the invention also find use in the treatment
of
dermatological inflamxnatory disorders, wherein the primary pharmacological
agent included
is a corticosteroid. Particularly contemplated is the treatment of
corticosteroid-responsive
inflammatory conditions, such as atopic dermatitis or eczema, seborrheic
dermatitis, some
forms of psoriasis, aphthous ulcers (canker sores), superficial skin lesions
due to contact with
poisonous plants such as poison oak or poison ivy, insect bites, and other
skin rashes of
unknown etiology. Steroidal agents of all different grades (1-7) that are
known in the art can
be inch.ided in a biological dressing preparation, such as betamethasone
(0.025% to 0.1%),
clobetasol (0.05%), diflorasone (0.05%), anlcinonide (0.1%), desoxiinetasone
(0.05% to
0.25%), fluocinonide (0.05%), halsinonide (0.1%), triamcinolone (0.025% to
0.5%),
hydrocortisone (0.1% to 2.5%), flurandrenolide (0.05%), alclometasone (0.05%),
fluocinolone
(0.01% to 0.2%), desonide (0.05%), desamethasone (0.1%) and methylprednisolone
(1.0%),
clocortolone (0.1%), fluticasone (0.005% to 0.05%), mometasone (0.1%),
prednicarbate
(0.1%), amcinonide (0.1%), andhalobetasole (0.05%). The particular
corticosteriodal agent
selected will depend on the patient and the particular disorder being treated.
[0027] For the treatment of certain skin disorders, non-steroidal drugs may be
appropriate.
As an example, a composition comprising one or more resins or other film-
forming agents and
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
11
salicylic acid (0.5% to 60%) and/or retinoic acid (Retin-A) (0.025% to 0.05%)
would be
suitable for the treatment of acne, psoriasis, warts, and other
hyperkeratotoic disorders.
Cantharidin (0.7%) and imiquimod (5%) are other examples of pharmacological
agents for use
in a biological dressing prepared for the treatment of warts, including
genital warts. Other
pharmacological agents suitable for the treatment of acne include tretinoin
(0.025% to 0.2%),
isotretinoin, adapaline (0.1 %), azelaic acid (20%), clindamycin,
erythromycin, tetracycline,
benzoyl peroxide (2.5% to 10%), and sulfacetainide (10%). A coinposition
coinprising one or
more resins or other film-forming agents and metronidazole (0.75%) finds use
in the treatment
of rosacea.
[0028] Biological dressings comprising anthralin (0.1% to 0.5%), calcipotriene
(0.005%)
and/or tazarotene find use in the treatment of psoriasis.
[0029] For certain inflammatory dermatological conditions, it may be desirable
to include
one or more anti-histamine compounds with a steroidal coinpound in the
biological dressing
compositions to aid in relieving itching that is often associated with
inflammatory lesions.
Histamine Hl and H2 receptor blockers known in the art are of use in the
preparation of
biologic dressings for treating certain inflammatory skin conditions include
the Hl blockers
astemizole and terfenadine, and the H2 blocker cimetidine.
[0030] Deimatological conditions which can be treated with phamacological
compositions
in which an anti-histainine is the primary agent include urticaria, and
itching associated with
lymphoproliferative diseases such as polycytheinia rubra vera and Hodglcin's
disease.
Oftentimes best results are achieved when using both an H1 and an H2 blocker.
Additionally,
a medicated biologic dressing comprising the anti-pruritic doxepin (5%) finds
use in relieving
the itching in patients with certain types of eczema. Topical doxepin appears
to work by
preventing the effects of histamine.
[0031] A biologic dressing of the invention also finds use in the treatment of
superficial
dematological viral infections, whenever topical anti-viral medications would
be indicated.
Particularly considered is the administration of acyclovir (5%) for the
treatment of viral
infections caused by herpes (type 1 and type 2) siinplex vinises, but a
biological dressing can
also be applied to superficial slcin infections caused by papillomavirus (for
exan7ple, connnon
and genital warts). Other examples of anti-viral agents for use in a
biological dressing include
gancyclovir, penciclovir (1%), vidarabine (3%), idoxuiidine (0.5%) and
trifluridine.
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
12
[0032] A resin-based biological dressing also finds use in providing relief
from pain
associated with the lesions caused by some derinatological disorders.
Particularly considered
is treatinent of the dermal pain that can be associated with varicella-zoster
virus (shingles,
chicken pox) with a topically compatible local aiiesthetic. A preferred
pharmacological agent
for use in a resin-based dressing prepared for treating pain associated with
dermatological
disorders is lidocaine (0.5% to 25%, see USPN Nos. 5,709,869, 5,601,838,
5,589,180 and
5,411,738, incorporated herein by reference). Other local anesthetics
cheinically and/or
pharmacologically related to lidocaine, or lidocaine hydrochloride, include
bupivacaine
hydrochloride (0.25% to 1.5%), etidocaine hydrochloride (1.0% to 3.0%),
mepivacaine
hydrochloride (1.0% to 5.0%), prilocaine hydrochloride (4.0% to 8.0%), and
tetracaine
hydrochloride (0.5% to 2.0%). Other preferred local anesthetics are those with
low solubility
in water, and which are particularly suited for sustained local anesthetic
action when topically
applied. Examples of local anesthetics with low solubility in water include
benzocaine and
the hydroiodide salt of tetracaine. Additional local anesthetics used in
treating mucous
membranes and the skin include dibucaine, dyclonine hydrochloride (0.5% to
1.0%), and
pramoxine hydrochloride (1.0%). Another example of a pharmacological agent
used
topically to relieve dei7natological pain includes capsaicin (0.025%).
[0033] A composition comprising one or more resins or other film-forming
agents
additionally finds use in surgical preparations for sustained release of
antiseptics. Examples of
active agents suitable for use in a resin-based biological dressing for
surgical preparations
include, but are not limited to biguanides such as chlorhexidene gluconate and
alexidine,
povione iodine, iodine, halogen releasing agents such as iodophor, diamidines,
anilides such as
triclocarban, phenols, halophenols and bis-phenols such as triclosan,
peroxygens such as
hydrogen peroxide, silver compounds such as silver nitrate and quartemary
ammonium
compounds.
[0034] Compositions comprising one or more resins or other film-forming agents
and
containing synthetic hormones find use in the treatment of indications
associated with
abnornial hormone production as well as contraception. For example, a biologic
dressing
containing transdermal testosterone, generally about 2.5-5.0 mg per
application, or equivalent
other androgenic compound(s) in an appropriate amount can be used to treat
young males
with congenital or acquired primary hypogonadism, or congenital or acquired
hypogonadotropic hypogonadism and other similar disorders. In women, a bilogic
dressing
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
13
containing estradiol (an active form of estrogen) or other equivalent
estrogenic compound(s)
in an appropriate amount, can be used to treat the indications and symptoms
associated with
atrophic vaginitis, atrophic dystrophy of the vulva, menopausal symptoms,
female
hypogonadism, ovariectomy, primary ovarian failure, non-steroid dependent
inoperable breast
cancer and vasomotor symptoms associated with menopause and prevention of post-
menopasual osteoporosis. A biologic dressing containing an estrogenic
compound, such as for
example estradiol in an amount sufficient for the treatment of such
indications is used.
[0035] A composition comprising one or more resins or other film-forming
agents and
containing norethindrone (progestin) can be used to prevent pregnancy by
inhibiting ovulation
and thickening the inucosa of the cervix. In addition, a film-forming resin or
other film-
forming agent composition containing a progestin compound such as
norethindrone (0.14-0.25
mg per application) can be used for treating abnormal menstrual disorders such
as
amenorrhea, abnormal uterine bleeding and endoinetriosis, applications
generally will be to
the skin. The site of application of the film-forming resin or other fihn-
forming agent
composition will vary depending upon the intended use. Generally the site of
application will
be to the skin at a location that will provide for absorption into the blood
stream. Particularly
in the case of treatments relating to the female genitalia, application can be
intravaginally.
[0036] Film-forming resin or other film-forming agent compositions are also
suitable for
sustained delivery of pharmacological agents use for hair growth retardation
and stimulation.
For treatments intending to stimulate hair growth; compositions comprising
minoxidil (1% to
5%) are prepared. For other topical formulations that can be used with the one
or more resins
or other film-forming agents, see USPN 6,184,249. For treatment intending to
retard hair
growth compositions comprising efloniithine hydrochloride (13.9%) are
prepared.
[0037] A composition comprising one or more resins or other fihn-forming
agents
additionally finds use in preparing protective compositions comprising one or
more sun
protecting, ultraviolet absorptive agents. Sunscreens for use in a film-
forming resin or other
film-forming agent-based dressing include aminobenzoate agents, such as p-
aininobenzoic
acid (PABA), etliyl 4-[bis(hydroxypropyl)] aminobenzoate, octyl dimethyl PABA,
PABA
propoxylate, glyceral PABA, 2-ethylhexyl PABA and pentyl PABA; cinnamate
agents, such
as cinoxate, diethanolamine-p-methoxy cinnainate, 2-ethylhexyl-p-
methoxycimiamate and
octyl methoxycinnamate; benzones, such as oxybenzone, dioxybenzone,
sulisobenzone;
salicylates, such as 2-ethylhexyl salicylate, triethanol ainine salicylate,
and octyl salicylate;
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
14
and other sunscreen agents, such as meradimate (7.5%), octinoxate (7.5%),
homosalate (10%),
sulisobenzone (10%), titanium dioxide and zinc oxide. For use as a sunscreen,
generally a thin
combination of one or more resins or other film-forming agents/ultraviolet
absorptive agents
is applied to areas of the skin that will be exposed to the sun. For some
situations, protection
of exposed skin from the sun will be best accomplished by applying a thiclcer
formulation of
the one or more resins or other fihn forming agents. For example, application
of sunscreen to
protect the skin of the nose at high altitudes. Advantageously, a formulation
comprising one
or more resins or otlier film-forming agents and sunscreen compound is
particularly effective
at providing long-lasting sun protection to exposed skin through resisting
removal by
abrasion or moisture.
[0038] Compositions comprising one or more resins or other film-forming agents
may be
prepared with pharmacological agents used for pigmenting or de-pigmenting the
skin, for
instance, for use in treating patients with vitiligo. For treatinents
intending to de-pigment or
lighten isolated dermal areas, a pharmacologic composition comprising
liydroquinone (2% to
4%) is prepared. For treatments intending to pigment desired areas of skin, a
composition
comprising a psoralen agent, such as methoxalen (1.0%), for combined use with
UV light, is
prepared.
[0039] A medicated resin-based dressing will also find use in the sustained
delivery of
anti-perspirants, anti-ainginal, anti-nausea agents and anti-cancer agents.
Particularly
conteinplated are compositions comprising aluminum chloride (20%), for the
inhibition of
perspiration of isolated dermal areas, for instance to aid in carrying out
surgical procedures.
A composition comprising one or more resins or other film forming agents and
nitroglycerin
(0.5% to 2.0%) will find use in the sustained transderinal delivery of this
anti-anginal agent
which can provide relief from chest pains. Relief from nausea, due to motion
siclcness for
example, can be provided using a biological dressing comprising scopolamine.
For anti-
nausea purposes, a composition comprising one or more resins or other film-
forming agents
and scopolarnine would be applied, behind the ear for exainple, before the
onset of activity
that potentially would induce nausea. Additionally, a resin or otlier film-
forming agent
dressing can be prepared for the sustained delivery of pharmacological agents
useful in the
treatment of superficial cancerous and pre-cancerous lesions. Particularly
contemplated is the
treatment of isolated actinic lceratosis lesions with a biological dressing
comprising 5-
fluorouracil (5-FU; 5% to 10%).
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
[0040] A composition comprising one or more resins or other film-forming
agents may
also be prepared with an insect repellant as the pharmacologic agent. Examples
of insect
repellant compounds suitable for inclusion in a resin-based biological
dressing include
terpenoids, such as citronellal, geraniol, terpentine, pennyroyal, cedarwood,
eucalyptus and
wintergreen; benzoquinones; aromatics, such as cresols, benzaldehyde, cinnamic
aldehyde,
benzoic acids; and synthetic insect repelling agents, such as N,N-diethyl-m-
toluamide
(DEET), ethyl hexanediol, dimethyl plithalate, dimethyl ethyl lzexanediol,
carbate,
butopyronoxyl, di-n-propyl isocinchonmeronate, N-octyl bicycloheptene,
dicarboximide, and
2,3,4,5-bis(2-butylene)tetra-hydro-2-furaldehyde. For use as an insect
repellent, a resin or
other film-forming agent preparation is preferably applied as a thin coat to
areas of the slcin
most likely to be attacked by an insect. Preferably, the insect repellant
compound used repels
insects without irritating the skin. Advantageously, as witli the sunscreen
preparations
described above, a composition comprising one or more resins or other film-
forming agents
and insect repellent is particularly effective at providing long-lasting
insect repellency on the
slcin through resisting removal by abrasion or moisture.
[0041] The compositions of the invention also find use in the treatment of
drug addiction.
Compositions comprising one or inore resins or other film-fonning agents may
be prepared
with nicotine, generally about in an amount sufficient to decrease nicotine
addition, 14-22
mg per application, or other amounts as appropriate, for use in the reduction
and/or cessation
of cigarette smoking, cliewing tobacco or other nicotine containing compounds.
The
compositions are applied to the slcin in a location that provides sufficient
absorption of the
nicotine, typically the upper arm. As the need for nicotine decreases the
dosage of nicotine in
the composition can be adjusted downward.
[0042] Optionally, the biologic dressings of the invention may include a
penetration
enhancer, i.e., a chemical compound that, when included in a formulation,
temporarily
increases the permeability of the skin to a drug allowing more of the drug to
be absorbed in a
shorter period of time. Examples of penetration enhancers that can be used
include
dimethylsulfoxide (DMSO), n-decyl methyl sulfoxide, N,N-dimethylacetamide, N,N-
methyl-2-
pyrrolidone and octylphenylpolyethylene glycols.
[0043] The biologic dressings of the invention may also include one or more
other
pharmaceutically acceptable carriers as needed that do not adversely affect
the effectiveness of
the drug, or the resinous delivery vehicle and do not daniage the skin to
which it is applied.
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
16
Suitable pharmaceutical carriers include sterile water; saline, dextrose;
dextrose in water or
saline; condensation products of castor oil and ethylene oxide combining about
30 to about
35 moles of ethylene oxide per mole of castor oil; liquid acid; lower
alkanols; oils such as
corn oil; olive oil, peanut oil, sesame oil, wintergreen oil, lanolin oil and
the lilce, with
emulsifiers such as mono- or di-glyceride of a fatty acid, or a phosphatide,
e.g., lecithin, and
the like; glycols; polyallcylene glycols; aqueous media in the presence of a
suspending agent,
for example, sodium carboxymethyl-cellulose; sodium alginate; poly(vinyl
pyrrolidone); and
the like, alone, or witli suitable dispensing agents such as lecithin;
polyoxyethylene stearate;
and the like. The carrier may also contain adjuvants such as preserving,
stabilizing, wetting,
emulsifying agents and the like.
[0044] The compounds of this invention can be administered in conjunction with
a
transdermal patch that can include the phaimacologic agent in a suitable
solvent system with
the one or more film-forming agents and a polyester patch. The compounds of
the present
invention also can be delivered through mucosal membranes. Transmucosal (i.e.,
sublingual,
buccal, and vaginal) drug delivery provides for an efficient entry of active
substances to the
systemic circulation and reduces immediate metabolism by the liver and
intestinal wall flora.
Transmucosal drug dosage fornls are held in contact with the mucosal membrane
where they
disintegrate and/or dissolve rapidly to allow immediate systemic absorption.
The method of
manufacture of these formulations is laiown in the art.
[0045] For aerosol administration, the pharmaceutical compositions are
preferably supplied
in finely divided form together with a surfactant and propellant as
pharmaceutically
acceptable carriers. The surfactant is nontoxic, and preferably soluble in the
propellant.
Representative of such agents are the esters or partial esters of fatty acids
containing from 6
to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic,
linoleic, linolenic,
olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic
anhydride. Mixed
esters, such as inixed or natural glycerides, can be einployed.
[0046] In practicing a method of treating the symptoms of a dermatological
disease in a
patient, the pharmacological conzposition in its original prepared form, is
applied directly and
specifically on the lesions or other damaged areas of slcin requiring
treatment. The biological
dressing composition may initially be prepared in any fornz suitable for
topical application,
such as a paste, a liquid, a semi-solid, a gel, a suspension, an emulsion or
the like, provided
that the fonnulation allows the one or more resins or other film-forming
agents and the one or
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
17
more phannacologically active agent to effectively adhere together to the skin
surface to
which they are applied and to form a protective barrier over the skin once the
volatile solvent _
has evaporated. To minimize waste, application is generally carried out by
painting or
swabbing the composition at the affected site or sites, but certain
preparations can also be
applied by spraying on the formulation, and allowing it to diy.
[0047] The biologic dressing composition can be applied wherever the patient
has
superficial skin lesions or infections, such as on cutaneous areas,
fingemails, toenails, mucous
membranes, and mucocutaneous junctions (i.e., perianal, intertriginous and
vulvovaginal
areas). After application, the volatile solvent evaporates to leave a
protective solidified,
adherent and hydrophobic film or coating on the skin surface to which it has
been applied.
The solidified film residue comprises the one or more resins or other film-
forming agents, and
the one or more pharmacologically active agents. By forming a barrier holding
the
pharmacologically active agent or agents to the surface, the combined film-
forming resins or
other film-forming agents permit a sustained, continuous release and a
prolonged exposure to
the agent or agents. Continuous exposure of the skin to the medication is
maintained as long as
the coating stays in place. The biologic dressing, therefore can effect
symptomatic relief with
less frequent applications. For most dermatological disorders treated using a
resin or other
film-forming agent-based dressing, one or two daily applications will be
sufficient to promote
regression or disappearance of the targeted skin lesions. For certain less
respondent lesions,
three daily applications may be required to effect disappearance of symptoms.
Other
dermatological disorders may require application every second day to realize
symptomatic
relief. The composition conveniently can be removed at will, by application of
an appropriate
solvent, normally ethanol. The composition can also be removed by scrubbing
with soap and
water.
[0048] The subject compositions can be provided for use in one or more
applications. For
treatment witli a pharmaceutical composition coinprising an agent identified
as one which is
effective in treating the symptoms of a disease amendable to treatment by
dermal application
of medication, the subject compositions can be provided as lcits for use in
one or more doses.
The kits include containers which can also constitute a delivery system,
holding a
composition comprising an effective agent either as concentrates (including
lyophilized
compositions), which may be fiirther diluted prior to use or they may be
provided at the
concentration of use, where the containers may include one or more dosages.
Conveniently, in
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
18
the kits single dosages can be provided in sterile containers so that the
physician or the patient
may employ the containers directly, where the containers have the desired
amount and
concentration of agents. When the containers contain the fornnulation for
direct use, usually
there will be no need for other reagents for use with the method. The kits
also can be in the
fomi of a transdermal or transmucosal system for single or multiple
applications. The
containers can be made of plastic, glass, metal or such material deemed
appropriate for each
particular medication and can be light opaque as required for light sensitive
formulations. The
containers can be color-coded, each color being unique to a particular product
and its
respective active ingredient. The containers can also be color coordinated
with the outer
packaging to siinplify marketing and consumer purchasing. Examples of
containers that are
also delivery systems are those that facilitate application of the subject
compositions to the
slcin or mucosa. The delivery systems can be any of a wide assortment of types
of applicators
(e.g. bottles), shapes and sizes of containers such as roll-on, spray with
either a manual or
aerosolized delivery system, applicators with small padded applicator tips for
the delivery of
buccal inucosal medications or syringe type applicators for semisolid
medication such as are
described in USPN 5,531,703 and references cited therein, particularly for the
delivery of
vaginal mucosal medications.
[0049] The subject compositions can be contained in packaging material, which
comprises
a label indicating that the subject compositions can be used to treat
dermatologic disorders in
humans or to treat other disorders in humans using transdermal delivery means.
[0050] The invention now being generally described, it will be more readily
understood by
reference to the following examples which are included for purposes of
illustration only and
are not intended to limit the present invention.
EXAMPLE 1
Treatment of athlete's foot (tinea pedis) with a resin-based biological
dressing
comprised of tinture of benzoin and clotrimazole
[00511 Tincture of benzoin compositions are produced with standard tincture of
benzoin
(3M, Minneapolis, MN). Replicated experiments were performed with a
composition
comprising tincture of benzoin with 90% alcohol ph.is 1% clotrinzazole. The
experiments
were repeated using mastic guin and elemi gtim tinctures as well. To determine
efficacy in
treating athlete's foot, the benzoin/clotrimazole coinposition was applied to
cases of athlete's
foot, replicated 5 times. In each replicate, the composition led to complete
clearance of the
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
19
athlete's foot within 1 weelc, when applied twice daily for 7 days. No
allergic reaction was
noted in this test, although the alcohol component reportedly led to stinging
when applied to
deep fissures. Minimal lint from the socks was noted on the coating where the
composition
was applied but was easily removed with ethanol. Efficacy of the
benzoin/clotrimazole
composition was compared to controls of tincture of benzoin alone and no
treatment. The
benzoin/clotrimazole composition provided symptoinatic relief and led to
healing more
quickly than tincture of benzoin alone, though tincture of benzoin alone
improved symptoms
and signs more quickly when compared to no treatment. This is likely due to
the fact that the
sticlcy coating from the tincture tends to repel moisture. Efficacy of the
benzoin/clotrimazole
composition also was compared to commercially available medications such as
LamisilOO,
LotriminOO, MycelexOO and Tinactin . In comparison, the benzoin/clotrimazole
composition
greatly decreased the time necessary for treatment compared to formulations of
each of the
coinmercial medications, particularly when the commercial medications were
administered in
the form of powder, liquid, solution, spray or gel. The benzoin/clotrimazole
composition
also decreased the time necessary for treatment when compared to cream
versions of the
above medications and was much less messy than any of the commercial
preparations tested.
EXAMPLE 2
Treatment of onychomycosis (tinea unguium) with a film-forming resin-based
biological
dressing comprised of tinture of mastic gum and ciclopirox
[0052] Tincture of mastic gum (Mastisol) coinpositions are produced witli
standard
Mastisol (Ferndale Laboratories in Femdale, MI). Replicated experiments were
performed
with a composition comprising tincture of mastic gum with 82% alcohol plus 8%
Ciclopirox.
To determine efficacy in treating onychomycosis, the mastic gum/ciclopirox
coniposition was
applied to cases of onychomycosis, replicated 6 times. In each replicate, the
composition led
to significant improvement of the onychomycosis within 6 weeks, when applied
once daily
for 6 weeks. No allergic reaction was noted in this test. Minimal lint from
the socks was
noted on the coating where the coinposition was applied but was easily removed
with
ethanol. Efficacy of the mastic gum/ciclopirox composition was compared to
controls of
tincture of mastic gum alone and no treatment. The mastic gum/ciclopirox
composition
provided symptomatic relief and led to healing more quiclcly than tincture of
mastic gum
alone, though tincture of mastic gum alone in7proved symptoms and signs more
quicldy when
compared to no treatment. This is lilcely due to the fact that the sticley
coating from the
tincture tends to repel moisture. Efficacy of the mastic gum/ciclopirox
composition also was
CA 02629810 2008-05-07
WO 2007/056491 PCT/US2006/043572
compared to commercially available medications such as PenLac . In comparison,
the
mastic gum/ciclopirox composition greatly decreased the time necessary for
treatment
compared to formulations of each of the commercial medications, particularly
when the
commercial medications were administered in the form of powder, liquid,
solution, spray or
gel. The mastic gurn/ciclopirox composition also decreased the time necessary
for treatment
wllen coxnpared to creain versions of the above medications and was much less
messy than
any of the commercial preparations tested.
[0053] The above results demonstrate the improved syinptomatic relief from a
disorder
that can be achieved by administering a topically acceptable pharmacological
agent in a film-
forming resin carrier that forms a biological bandage in comparison presently
available
carriers. With a film-forming resin-based biological dressing, relief from the
unpleasant
symptoms associated with a dermatological lesion is realized more efficiently
and in a more
convenient and palatable manner.
[0054] All publications and patent applications inentioned in this
specification are
indicative of the level of skill of those skilled in the art to which this
invention pertains. All
publications and patent applications are herein incorporated by reference to
the same extent as
if each individual publication or patent application was specifically and
individually indicated
to be incorporate by reference.
[0055] Although the invention has been described with reference to the above
example, it
will be understood that modifications and variations are encompassed within
the spirit and
scope of the invention. Accordingly, the invention is limited only by the
following claims.
